About this Research Topic
The nocebo effect refers to the worsening of symptoms or adverse events that are related either to a placebo or an active treatment, caused either by environmental factors or interindividual variables related to the person receiving the treatment, but not to the pharmacological or physiological effects of the therapy. The nocebo effects may make treatment ineffective or harmful, and, therefore, it distorts the outcome in biomedical experiments, clinical trials, and every-day practice.
Understanding the neurobiological mechanisms and recognition of serious negative consequences of nocebo, such as a lack of adherence or discontinuation of a trial or a
therapy is important but is much less studied than the placebo effects. For example, in PubMed, there are over 300 more publications citing “placebo” or "placebo effects"; than "nocebo" or "nocebo effects".
The aim of this Research Topic, in line with the topical workshop during the IASP 2021 World Congress on Pain, is to raise awareness of the existence of nocebo effect in clinical practice and research and to stimulate discussion on how to minimize it in order to develop personalized and more effective treatment approaches. We would like to encourage the debate by preparing a research topic including original research studies, meta-analyses, and mini-reviews.
The Topic Editors will be hosting the Workshop at the next IASP VIRTUAL SERIES ON PAIN & EXPO- INNOVATION IN RESEARCH AND EDUCATION on Thursday, 11 February 2021 (9:00 AM – 10:30 AM)
Is Nocebo Placebo's Evil Twin?
Chair: Karolina Wartolowska, – Clinical Research Fellow, Nuffiled Department of Clinical Neurosciences, University of Oxford
Speaker: Luana Colloca, – Associate professor, Pain Translational Symptoms Science, University of Maryland
Speaker: Martina Amanzio, – Associate Professor , Department of Psychology, University of Turin
Link: https://www.eventscribe.com/2020/IASP-Virtual-Series-on-Pain/
Understanding the neurobiological mechanisms and recognition of serious negative consequences of nocebo, such as a lack of adherence or discontinuation of a trial or a
therapy is important but is much less studied than the placebo effects. For example, in PubMed, there are over 300 more publications citing “placebo” or "placebo effects"; than "nocebo" or "nocebo effects".
The aim of this Research Topic, in line with the topical workshop during the IASP 2021 World Congress on Pain, is to raise awareness of the existence of nocebo effect in clinical practice and research and to stimulate discussion on how to minimize it in order to develop personalized and more effective treatment approaches. We would like to encourage the debate by preparing a research topic including original research studies, meta-analyses, and mini-reviews.
The Topic Editors will be hosting the Workshop at the next IASP VIRTUAL SERIES ON PAIN & EXPO- INNOVATION IN RESEARCH AND EDUCATION on Thursday, 11 February 2021 (9:00 AM – 10:30 AM)
Is Nocebo Placebo's Evil Twin?
Chair: Karolina Wartolowska, – Clinical Research Fellow, Nuffiled Department of Clinical Neurosciences, University of Oxford
Speaker: Luana Colloca, – Associate professor, Pain Translational Symptoms Science, University of Maryland
Speaker: Martina Amanzio, – Associate Professor , Department of Psychology, University of Turin
Link: https://www.eventscribe.com/2020/IASP-Virtual-Series-on-Pain/
Keywords: biomedical experiments, randomized controlled trials, placebo control, nocebo effects, placebo effects
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
